Your search found 1 Results

  1. 1
    784568

    Cyproterone acetate (CPA) a potential male contraceptive: further studies on the interactions with endocrine parameters.

    MOLTZ L; ROMMLER A; SCHWARTZ U; POST K; HAMMERSTEIN J

    Berlin, Germany, WHO-CCCR, [1978]. 11 p.

    This unpublished paper is the transcript of a conference proceeding, but the figures referred to textually are not included in the document. This study evaluated the effects of medium dose cyproterone acetate (CPA), 10-30 mg/day, on gonadotropin and peripheral androgen levels. On the average, luteinizing hormone (LH) concentrations were about 35% lower during CPA administration; similar observations were made for follicle stimulating hormone (FSH). CPA medication resulted in a significant reduction of LH response to LH-releasing hormone (RH); FSH increments following LH-RH stimulation were considerably smaller than those of LH and were hardly distinguishable from spontaneous FSH fluctuations. LH-RH double stimulation resulted in a slow but continuous rise of T without distinct peaks of borderline significance. CPA administration caused a highly significant elevation of serum prolactin in 7/10 males. In summary, medium dose CPA exerted the following effects on the hypothalamo-pituitary-testicular axis during the 1st 12 weeks of administration: 1) suppression of basal LH, FSH, T, and dihydroT; 2) abolition of the spiking phenomenon of androgen secretion; 3) suppression of LH-RH mediated secretion of LH and FSH; and 4) elevation of basal prolactin.
    Add to my documents.